Immunogenic Proteins and Compositions

Patent metadata

Field	Value
Publication number	US-2016362457-A1
Application number	US-201615252930-A
Country	US
Kind code	A1
Filing date	Aug 31, 2016
Priority date	Apr 1, 2010
Publication date	Dec 15, 2016
Grant date	—

Abstract

The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus ; GBS)

First claim

1 . A polypeptide comprising at least two of:
a) a first polypeptide comprising a first amino acid sequence (i) consisting of a fragment of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:10 (D3), SEQ ID NO:36 (D3 sub-fragment), SEQ ID NO: 51 (D3+D4H) or SEQ ID NO:53 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:1 comprising the amino acid sequence of SEQ ID NO:10 (D3), SEQ ID NO:36 (D3 sub-fragment), SEQ ID NO: 51 (D3+D4H) or SEQ ID NO:53 (D2+D3+D4H); b) a second polypeptide comprising a second amino acid sequence (i) consisting of a fragment of SEQ ID NO:2 comprising the amino acid sequence of SEQ ID NO:14 (D3), SEQ ID NO:38 (D3 sub-fragment), SEQ ID NO:55 (D3+D4H) or SEQ ID NO:57 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:2 comprising the amino acid sequence of SEQ ID NO:14 (D3), SEQ ID NO:38 (D3 sub-fragment), SEQ ID NO:55 (D3+D4H) or SEQ ID NO:57 (D2+D3+D4H); c) a third polypeptide comprising a third amino acid sequence (i) consisting of a fragment of SEQ ID NO:3 comprising the amino acid sequence of SEQ ID NO:18 (D3), SEQ ID NO:40 (D3 sub-fragment), SEQ ID NO:59 (D3+D4H) or SEQ ID NO:61 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:3 comprising the amino acid sequence of SEQ ID NO:18 (D3), SEQ ID NO:40 (D3 sub-fragment), SEQ ID NO:59 (D3+D4H) or SEQ ID NO:61 (D2+D3+D4H); d) a fourth polypeptide comprising a fourth amino acid sequence (i) consisting of a fragment of SEQ ID NO:4 comprising the amino acid sequence of SEQ ID NO:22 (D3), SEQ ID NO:42 (D3 sub-fragment), SEQ ID NO:63 (D3+D4H) or SEQ ID NO:65 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:4 comprising the amino acid sequence of SEQ ID NO:22 (D3), SEQ ID NO:42 (D3 sub-fragment), SEQ ID NO:63 (D3+D4H) or SEQ ID NO:65 (D2+D3+D4H); e) a fifth polypeptide comprising a fifth amino acid sequence (i) consisting of a fragment of SEQ ID NO:5 comprising the amino acid sequence of SEQ ID NO:26 (D3), SEQ ID NO:44 (D3 sub-fragment), SEQ ID NO:67 (D3+D4H) or SEQ ID NO:69 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:5 comprising the amino acid sequence of SEQ ID NO:26 (D3), SEQ ID NO:44 (D3 sub-fragment), SEQ ID NO:67 (D3+D4H) or SEQ ID NO:69 (D2+D3+D4H); f) a sixth polypeptide comprising a sixth amino acid sequence (i) consisting of a fragment of SEQ ID NO:6 comprising the amino acid sequence of SEQ ID NO:30 (D3), SEQ ID NO:46 (D3 sub-fragment), SEQ ID NO:71 (D3+D4H) or SEQ ID NO:73 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% sequence identity to a fragment of SEQ ID NO:6 comprising the amino acid sequence of SEQ ID NO:30 (D3), SEQ ID NO:46 (D3 sub-fragment), SEQ ID NO:71 (D3+D4H) or SEQ ID NO:73 (D2+D3+D4H); and g) a seventh polypeptide comprising a seventh amino acid sequence (i) consisting of a fragment of SEQ ID NO:7 comprising the amino acid sequence of SEQ ID NO:34 (D3), SEQ ID NO:48 (D3 sub-fragment), SEQ ID NO:75 (D3+D4H) or SEQ ID NO:77 (D2+D3+D4H); or (ii) consisting of a sequence having at least 90% identity to a fragment of SEQ ID NO:7 comprising the amino acid sequence of SEQ ID NO:34 (D3), SEQ ID NO:48 (D3 sub-fragment), SEQ ID NO:75 (D3+D4H) or SEQ ID NO:77 (D2+D3+D4H).

2 . The polypeptide of claim 1 , comprising amino acid sequence:
A-{—X-L} n -B
wherein:
each X is an amino acid sequence of first polypeptide, second polypeptide, third polypeptide, fourth polypeptide, fifth polypeptide, sixth polypeptide, or seventh polypeptide as defined in claim 1 and wherein each X is a different polypeptide;
L is an optional linker amino acid sequence;
A is an optional N terminal amino acid sequence;
B is an optional C terminal amino acid sequence; and
n is an integer of 2 or more.

3 . An immunogenic composition comprising a polypeptide according to claim 1 and one or more pharmaceutical carrier(s) and/or excipient(s).

4 . A nucleic acid comprising a nucleotide sequence encoding the polypeptide of claim 1 .

5 . A method or treating an infection caused by GBS in a mammal, comprising administering to the mammal an effective amount of a polypeptide according to claim 1 or a nucleic acid encoding the polypeptide.

6 . The method of claim 5 , wherein the infection is meningitis.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Grandi Guido
• Maione Domenico
• Rinaudo Cira Daniela

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• C07K14/315 Primary

  from Streptococcus (G), e.g. Enterococci · CPC title